Progressive alteration of DNA methylation of Alu, MGMT, MINT2, and TFPI2 genes in colonic mucosa during colorectal cancer development.

Cancer Biomarkers : Section a of Disease Markers
Ben KangDong Sun Kim

Abstract

Colorectal cancer (CRC) is one of the leading causes of mortality and morbidity in the world. It is characterized by different pathways of carcinogenesis and is a heterogeneous disease with diverse molecular landscapes that reflect histopathological and clinical information. Changes in the DNA methylation status of colon epithelial cells have been identified as critical components in CRC development and appear to be emerging biomarkers for the early detection and prognosis of CRC. To explore the underlying disease mechanisms and identify more effective biomarkers of CRC. We compared the levels and frequencies of DNA methylation in 11 genes (Alu, APC, DAPK, MGMT, MLH1, MINT1, MINT2, MINT31, p16, RGS6, and TFPI2) in colorectal cancer and its precursor adenomatous polyp with normal tissue of healthy subjects using pyrosequencing and then evaluated the clinical value of these genes. Aberrant methylation of Alu, MGMT, MINT2, and TFPI2 genes was progressively accumulated during the normal-adenoma-carcinoma progression. Additionally, CGI methylation occurred either as an adenoma-associated event for APC, MLH1, MINT1, MINT31, p16, and RGS6 or a tumor-associated event for DAPK. Moreover, relatively high levels and frequencies of DAPK, M...Continue Reading

References

Jul 21, 1999·Proceedings of the National Academy of Sciences of the United States of America·M ToyotaJ P Issa
Mar 10, 2001·Nature·E S LanderUNKNOWN International Human Genome Sequencing Consortium
Aug 3, 2002·Oncogene·Melanie Ehrlich
Mar 26, 2003·The American Journal of Pathology·Carolyn BariolRobyn Ward
Jan 20, 2006·British Journal of Cancer·K KawakamiB Iacopetta
Jun 5, 2007·Current Problems in Cancer·John KauhMitchell Berger
Dec 19, 2009·The New England Journal of Medicine·Sanford D Markowitz, Monica M Bertagnolli
Feb 6, 2010·Cancer Metastasis Reviews·Myoung Sook KimDavid Sidransky
Apr 15, 2011·Journal of Biomedicine & Biotechnology·Lucia MiglioreFabio Coppedè
Aug 13, 2011·The American Journal of Surgical Pathology·Kyoung-Mee KimRobert Daniel Odze
Oct 10, 2012·Endocrine-related Cancer·Cuong V DuongWilliam E Farrell
Apr 25, 2014·Gastroenterology Report·Yanxin LuoWilliam M Grady
Dec 15, 2015·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Yang LuoMing Zhong
Mar 2, 2016·Epigenetics : Official Journal of the DNA Methylation Society·Mark O KitchenWilliam E Farrell
Mar 15, 2016·Cancer Letters·Yoshifumi BabaHideo Baba
Jun 22, 2016·Virchows Archiv : an International Journal of Pathology·Mike F MüllerMark J Arends
Jul 20, 2016·World Journal of Gastroenterology : WJG·Parisa Aghagolzadeh, Ramin Radpour
Feb 15, 2017·Proceedings of the National Academy of Sciences of the United States of America·Michael KlutsteinHoward Cedar
Jun 19, 2017·BMC Bioinformatics·Reiko NishiharaJukka-Pekka Onnela
Nov 13, 2019·Proceedings of the National Academy of Sciences of the United States of America·Iradj SobhaniPhilippe J Sansonetti

❮ Previous
Next ❯

Citations

Jul 3, 2021·Oncology Reports·Can Kong, Tao Fu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Adenomatous Polyposis Coli

Adenomatous polyposis coli is a protein encoded by the APC gene and acts as a tumor suppressor. Discover the latest research on adenomatous polyposis coli here.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.